Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
First Claim
Patent Images
1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which specifically hybridizes and is at least 95% complementary to a natural antisense polynucleotide having SEQ ID NO;
2 and upregulates the function and/or expression of a Fibroblast growth factor 21 (FGF21) gene in vivo or in vitro as compared to a normal control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense of oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.
197 Citations
15 Claims
-
1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which specifically hybridizes and is at least 95% complementary to a natural antisense polynucleotide having SEQ ID NO;
2 and upregulates the function and/or expression of a Fibroblast growth factor 21 (FGF21) gene in vivo or in vitro as compared to a normal control. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- at least one modified sugar moiety;
Specification